



NEWS RELEASE

Ocumetics Announces Scientific Advisory Committee to Support Advancing Clinical and Regulatory Strategy

For Immediate Release

Calgary, Alberta – February 26, 2026 - Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in next generation ophthalmic technology, today announced the formation of a Scientific Advisory Committee (SAC) to support the Company’s advancing clinical, regulatory, and commercialization strategy as it progresses toward late-stage development.

The SAC will provide independent, multidisciplinary expertise across clinical trial design, regulatory strategy, surgical application, lens science, and translational research, ensuring strong clinical governance and informed decision making as Ocumetics prepares for pivotal clinical studies and future FDA engagement. The SAC will include Dr Ron Krueger, MD, MSE, a globally recognized ophthalmologist, surgeon, and innovator in refractive and cataract surgery.

Dr. Krueger brings decades of leadership in clinical research, surgical innovation, and technology translation, including extensive experience guiding ophthalmic devices through advanced clinical development. Dr. Krueger is the McGraw Professor and Chairman of Ophthalmology at the University of Nebraska Medical Center. He was previously on staff at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University and a senior staff surgeon at the Cleveland Clinic Cole Eye Institute. He is internationally recognized for his pioneering contributions to laser vision correction, cataract surgery, and presbyopia treatment, and has authored more than 300 peer-reviewed publications, book chapters, and scientific presentations. Dr. Krueger has served as a principal investigator in numerous clinical trials and has advised multiple ophthalmic device companies on clinical development, regulatory strategy, and surgical adoption.

“Dr. Krueger’s scientific rigor, clinical insight, and experience translating innovation into clinical practice make him an ideal addition to our Scientific Advisory Committee,” said Dean Burns, President and CEO of Ocumetics. “As we enter a more complex phase of development, this committee structure ensures we are drawing from the best collective expertise to guide our clinical execution and regulatory strategy.”

The Scientific Advisory Committee will function as a strategic advisory body, providing guidance on:

- Clinical trial design and endpoint optimization
- First-in-human and pivotal study execution
- Regulatory strategy and FDA engagement
- Surgical usability and adoption considerations
- Risk assessment and clinical governance
- Commercialization readiness and physician education

Additional members of the SAC will be announced in the coming months. Ocumetics remains focused on advancing its accommodating intraocular lens technology through clinical validation and regulatory milestones, with the goal of delivering innovative vision solutions to patients worldwide.

About Ocumetics

Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) is a Canadian research and product development company that is dedicated to developing advanced vision correction solutions that enhance the quality of life for patients. Through innovative research and development, Ocumetics aims to transform the field of ophthalmology with state-of-the-art intraocular lenses and other vision-enhancing technologies.

Ocumetics is in the first-in-human early feasibility study phase of a game-changing technology for the ophthalmic industry. Ocumetics has developed an intraocular lens that fits within the natural lens compartment of the eye, potentially to eliminate the need for corrective lenses. It is designed to allow the eye's natural muscle activity to shift focus from distance to near, providing clear vision at all distances without the help of glasses or contact lenses.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Dave Burwell
Director, Investor Relations
dave.burwell@ocumetics.com
(403) 410-7907

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This news release includes certain "forward-looking statements" under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to, statements with respect to the commencement, timing and scope of the research and development to be conducted by the Company mentioned above. Forward-looking statements are necessarily based upon a number

of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include but are not limited to: operational matters, historical trends, current conditions and expected future developments, access to financing as well as other considerations that are believed to be appropriate in the circumstances. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.